Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2024 · 10-Q
Revenue$30.98M$30.98M−29.6% vs Q1 2023 Net Income$86.14M$86.14M+105.3% vs Q1 2023 EPS Diluted$4.75$4.75+103.9% vs Q1 2023 Operating Income$2,988,000−79.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$18,627,000−40.9% Margins · derivedOperating margin9.6%−22.7 pt vs Q1 2023
Net margin278.1%+182.7 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end